{
    "2021-10-29": [
        [
            {
                "time": "",
                "original_text": "上海医药：前三财季盈利44.84亿人民币，同比增长24.49%",
                "features": {
                    "keywords": [
                        "上海医药",
                        "盈利",
                        "同比增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "云南白药炒股亏 11 亿，背后的操作手是谁？ 投资失误",
                "features": {
                    "keywords": [
                        "云南白药",
                        "炒股亏损",
                        "投资失误"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "上海医药(02607.HK)：前三季净利44.84亿元 同比增长24.49%",
                "features": {
                    "keywords": [
                        "上海医药",
                        "净利润",
                        "同比增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "上海医药：订立采购框架协议",
                "features": {
                    "keywords": [
                        "上海医药",
                        "采购框架协议"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "上海医药(601607.SH)：第三季度净利降20.94%至9.16亿元 盈利能力下降",
                "features": {
                    "keywords": [
                        "上海医药",
                        "净利下降",
                        "盈利能力下降"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "上海医药：2021年第三季度净利润约9.16亿元，同比下降20.94% 盈利能力下降",
                "features": {
                    "keywords": [
                        "上海医药",
                        "净利润",
                        "同比下降"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "上海医药：前三季度净利润同比增长24.49%",
                "features": {
                    "keywords": [
                        "上海医药",
                        "净利润",
                        "同比增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "我国制药产业不断获国际市场关注，License-out交易活跃",
                "features": {
                    "keywords": [
                        "制药产业",
                        "国际市场",
                        "License-out"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "不超2.925亿美元！上海医药将以将SPH6162海外权益许可给HU_YABIO",
                "features": {
                    "keywords": [
                        "上海医药",
                        "SPH6162",
                        "海外权益",
                        "许可"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "License out！超2.9亿美元上海医药SPH6162海外授权落地",
                "features": {
                    "keywords": [
                        "上海医药",
                        "SPH6162",
                        "海外授权"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}